Ormat Technologies closes $1 billion convertible notes offering
Get Alerts ORA Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 0.7%
Revenue Growth %: +2.9%
Join SI Premium – FREE
Ormat Technologies Inc. (NYSE: ORA) completed a $1 billion private offering of convertible senior notes, the geothermal energy company announced March 23.
The offering includes $825 million of 1.50% Series A Convertible Senior Notes and $175 million of 0.00% Series B Convertible Senior Notes, both due 2031. The notes were sold to qualified institutional buyers under Rule 144A of the Securities Act.
The Series A Notes carry a 1.50% annual interest rate payable semi-annually, while the Series B Notes do not bear regular interest. Both series mature March 15, 2031, unless converted, redeemed or repurchased earlier. The initial conversion price reflects a 30% premium over the company's stock price at pricing.
Holders of Series B Notes can require the company to repurchase their notes on March 15, 2027, at 100% of principal amount plus any accrued special interest.
Ormat used approximately $287.9 million of net proceeds, plus $25 million cash and about 0.6 million common shares, to repurchase $285.9 million of its existing 2.50% convertible notes due 2027 through private transactions. The company also used $25 million to repurchase common shares, with remaining proceeds designated for general corporate purposes.
"We elected to execute this capital raise in the convertible market as it provided us with the best combination of low and no cash coupon, financial flexibility, and the ability to reduce equity dilution versus other debt and equity financing alternatives," said Chief Executive Officer Doron Blachar.
Ormat operates geothermal and energy storage facilities with a current generating portfolio of 1,835MW across the United States, Kenya, Guatemala, Indonesia, Honduras and Guadeloupe.
You May Also Be Interested In
- Exclusive: National Vision’s CEO on why the market got post-Q1 selloff wrong
- Sanofi wins Japan approval for Sarclisa SC in multiple myeloma
- RedHill Biopharma sets $6M private placement with warrant upside
Create E-mail Alert Related Categories
Corporate News, Equity OfferingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share